The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of advers...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2020-07, Vol.4 (13), p.3072-3084
Hauptverfasser:	Maharaj, Kamira, Powers, John J., Achille, Alex, Mediavilla-Varela, Melanie, Gamal, Wael, Burger, Karen L., Fonseca, Renee, Jiang, Kun, Miskin, Hari P., Maryanski, Dave, Monastyrskyi, Andrii, Duckett, Derek R., Roush, William R., Cleveland, John L., Sahakian, Eva, Pinilla-Ibarz, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Heterocyclic Compounds, 4 or More Rings - therapeutic use Humans Immunobiology and Immunotherapy Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Mice Phosphatidylinositol 3-Kinases - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!